Responses
Clinical/translational cancer immunotherapy
Original research
Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.